Rvl Pharmaceuticals Plc Revenue Growth Rates (RVLP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Rvl Pharmaceuticals Plc  (NASDAQ: RVLP)
 

RVLP's Revenue Growth by Quarter and Year

Rvl Pharmaceuticals Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RVLP Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 7.31
1st Quarter March 8.83
FY 16.14

RVLPs Annual Revenue
Rvl Pharmaceuticals Plc's Revenue in the fiscal year 2022 $ 49.72 millions
Rvl Pharmaceuticals Plc's Revenue in the fiscal year 2021 $ 17.50 millions
Rvl Pharmaceuticals Plc's Revenue in the fiscal year 2020 $ 27.76 millions
Rvl Pharmaceuticals Plc's Revenue in the fiscal year 2019 $ 1.20 millions
Rvl Pharmaceuticals Plc's Revenue in the fiscal year 2018 $ 245.75 millions




RVLP Revenue second quarter 2023 Y/Y Growth Comment
Rvl Pharmaceuticals Plc reported fall in Revenue in the second quarter 2023 by -13.47% to $ 7.31 millions, from the same quarter in 2022.
The decline in the second quarter 2023 Rvl Pharmaceuticals Plc's Revenue compares unfavorably to the Company's average Revenue jump of 64.38%.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue growth. While Rvl Pharmaceuticals Plc' s Revenue decrease of -13.47% ranks overall at the positon no. 3160 in the second quarter 2023.


RVLP Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 243.01 % -91.72 % -42.36 %
3rd Quarter September - 355.45 % -91.46 % -60.66 %
2nd Quarter June -13.47 % -26.59 % 4904.35 % -99.6 %
1st Quarter March -58.82 % 2180.85 % -98.07 % -14.84 %
FY   - 183.95 % -83.96 % -

Financial Statements
Rvl Pharmaceuticals Plc's second quarter 2023 Revenue $ 7.31 millions RVLP's Income Statement
Rvl Pharmaceuticals Plc's second quarter 2022 Revenue $ 8.45 millions Quarterly RVLP's Income Statement


RVLP Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -2.1 % 30 % 34.1 %
3rd Quarter September - 18.58 % -80.89 % 11095.65 %
2nd Quarter June -17.19 % -60.59 % 1124.47 % -99.53 %
1st Quarter March -9.99 % 649.65 % -97.28 % -18.79 %
FY (Year on Year)   - 183.95 % -83.96 % -


Back to RVLP Growth rate Comparisons >> Back to RVLP Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #498
Overall #3160

Revenue Y/Y Growth Statistics
High Average Low
356.38 % 64.38 % -58.81 %
(Sep 30 2022)   (Mar 31 2023)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #498
Overall #3160
Revenue Y/Y Growth Statistics
High Average Low
356.38 % 64.38 % -58.81 %
(Sep 30 2022)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Rvl Pharmaceuticals Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
18.63 % -25.37 % -80.92 %
(Sep 30 2022)  


RVLP's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Rvl Pharmaceuticals Plc disclosed fall in Revenue from the first quarter by -17.19% to $ 7.31 millions, from $ 8.83 millions achived in the previous reporting period.

But that's not important problem, as Rvl Pharmaceuticals Plc's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 211 other companies have achieved higher Revenue quarter on quarter growth. While Rvl Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 3715.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #212
Healthcare Sector #568
Overall #3715
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #212
Healthcare Sector #568
Overall #3715
Revenue Q/Q Growth Statistics
High Average Low
18.63 % -25.37 % -80.92 %
(Sep 30 2022)  


RVLP's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Rvl Pharmaceuticals Plc disclosed fall in Revenue from the first quarter by -17.19% to $ 7.31 millions, from $ 8.83 millions achived in the previous reporting period.

But that's not important problem, as Rvl Pharmaceuticals Plc's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 211 other companies have achieved higher Revenue quarter on quarter growth. While Rvl Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 3715.


Rvl Pharmaceuticals Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 35.97 $ 37.11 $ 49.72 $ 42.77 $ 34.95
Y / Y Revenue Growth (TTM) 2.93 % -2.37 % 184.1 % -13.01 % -51.95 %
Year on Year Revenue Growth Overall Ranking # 356 # 369 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -3.06 % -25.37 % 16.24 % 22.39 % -8.06 %
Seq. Revenue Growth (TTM) Overall Ranking # 3234 # 3148 # 2246 # 106 # 3232


Cumulative Revenue growth Comment
Although Rvl Pharmaceuticals Plc's Annual Revenue growth year on year were below company's average 84.37% , Revenue announced in the Jun 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.93% year on year, from -2.37% in Mar 31 2023.

In the Healthcare sector 109 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 356, from total ranking in previous quarter at 369.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 110
Overall # 356

Revenue TTM Y/Y Growth Statistics
High Average Low
95.7 %
 84.37 %
73.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 170
Sector # 466
S&P 500 # 3234
Cumulative Revenue growth Comment
Although Rvl Pharmaceuticals Plc's Annual Revenue growth year on year were below company's average 84.37% , Revenue announced in the Jun 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.93% year on year, from -2.37% in Mar 31 2023.

In the Healthcare sector 109 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 356, from total ranking in previous quarter at 369.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 110
Overall # 356

Revenue TTM Y/Y Growth Statistics
High Average Low
95.7 %
84.37 %
73.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 170
Sector # 466
S&P 500 # 3234




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RVLP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Fortrea Holdings Inc -0.01%$ -0.013 millions
Aquestive Therapeutics Inc -0.18%$ -0.181 millions
Phibro Animal Health Corporation-0.34%$ -0.340 millions
Procyon Corporation-0.59%$ -0.589 millions
Amedisys Inc-0.88%$ -0.882 millions
Baxter International Inc -1.04%$ -1.041 millions
Healthcare Services Group Inc -1.39%$ -1.395 millions
Bio rad Laboratories Inc -1.54%$ -1.536 millions
Harvard Bioscience Inc -1.83%$ -1.832 millions
Embecta Corp -1.92%$ -1.924 millions
Procaps Group S a -2.10%$ -2.102 millions
Enhabit Inc -2.13%$ -2.127 millions
Icu Medical Inc-2.26%$ -2.260 millions
Tandem Diabetes Care Inc -2.26%$ -2.261 millions
West Pharmaceutical Services Inc -2.27%$ -2.269 millions
Coherus Oncology inc -2.39%$ -2.386 millions
Hookipa Pharma inc -2.44%$ -2.440 millions
Biolife Solutions Inc -2.53%$ -2.529 millions
Enanta Pharmaceuticals Inc-3.01%$ -3.014 millions
Nrc Health-3.03%$ -3.033 millions
Intellia Therapeutics Inc -3.11%$ -3.108 millions
Organogenesis Holdings Inc -3.36%$ -3.365 millions
Omniab Inc -3.51%$ -3.514 millions
Marker Therapeutics inc -3.52%$ -3.523 millions
Akumin Inc -3.79%$ -3.793 millions
Endo International Plc-3.91%$ -3.912 millions
Integra Lifesciences Holdings Corp-4.16%$ -4.160 millions
Vireo Growth Inc.-4.24%$ -4.237 millions
Sonendo Inc -4.26%$ -4.257 millions
Avinger Inc -4.27%$ -4.268 millions


About Rvl Pharmaceuticals Plc Revenue Growth Rates (RVLP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Rvl Pharmaceuticals Plc (CIK 1739426).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-23-014733
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Rvl Pharmaceuticals Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.